Pancreatic Cancer Research

ResearcherYokohama City UniversityActive in the last 2 years

Yasuhiro Yabushita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1090-1614; OpenAlex author ID A5012227908. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 6 papers · 2026: 1 paper

Papers 16

  1. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  2. Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study). First author DOI 10.1038/s41598-025-23608-5↗
  3. Clinical Relevance of High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transection Margin in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-17400-y↗
  4. ASO Author Reflections: A New Proposal for Therapeutic Strategies in Patients with High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transectio… Co-author DOI 10.1245/s10434-025-17508-1↗
  5. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  6. Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate Antigen 19-9 Levels in Patients With Resectable Pancreatic Cancer Treated With S-1 and Ge… Co-author DOI 10.14740/wjon2563↗
  7. Neoadjuvant Chemoradiotherapy Enhances Tumor PD-L1 Expression in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17554↗
  8. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.1245↗
  9. CRMP4 Up-regulates M2 Macrophages and Myeloid-derived Suppressor Cells to Promote Pancreatic Cancer in Mice. Co-author DOI 10.21873/anticanres.15537↗
  10. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy. Co-author DOI 10.1007/s00268-020-05503-4↗
  11. Low Incidence of High-Grade Pancreatic Intraepithelial Neoplasia Lesions in a Crmp4 Gene-Deficient Mouse Model of Pancreatic Cancer. Co-author DOI 10.1016/j.tranon.2020.100746↗
  12. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Fo… Co-author DOI 10.1007/s00268-019-05159-9↗
  13. MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negativ… Co-author DOI 10.1245/s10434-019-07793-y↗
  14. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative R… Co-author DOI 10.21873/anticanres.13615↗
  15. [III. Resection Margins and R1 Resection in Pancreatic Cancer]. Co-author PMID 30382038↗
  16. Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11587↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Itaru Endo · 16 shared papers, 2017–2026 · strength 2.73
  2. Kentaro Miyake · 6 shared papers, 2023–2025 · strength 1.44
  3. Yuki Homma · 8 shared papers, 2018–2025 · strength 1.41
  4. Takashi Murakami · 7 shared papers, 2019–2026 · strength 1.11
  5. Yukihiko Hiroshima · 4 shared papers, 2019–2025 · strength 0.59
  6. Kei Kobayashi · 2 shared papers, 2025 · strength 0.49
  7. Yoshiaki Murakami · 2 shared papers, 2025–2026 · strength 0.44
  8. Sohei Satoi · 2 shared papers, 2025–2026 · strength 0.44
  9. Shuji Isaji · 2 shared papers, 2025–2026 · strength 0.44
  10. Suguru Yamada · 2 shared papers, 2025–2026 · strength 0.44
  11. Masanori Oshi · 2 shared papers, 2025–2026 · strength 0.44
  12. Masayuki Sho · 2 shared papers, 2025–2026 · strength 0.44
  13. Hiroki Yamaue · 2 shared papers, 2025–2026 · strength 0.44
  14. Michiaki Unno · 2 shared papers, 2025–2026 · strength 0.44
  15. Satoshi Hirano · 2 shared papers, 2025–2026 · strength 0.44
  16. Goro Honda · 2 shared papers, 2025–2026 · strength 0.44
  17. Masayuki Ohtsuka · 2 shared papers, 2025–2026 · strength 0.44
  18. Nobuhiro Tsuchiya · 3 shared papers, 2019–2020 · strength 0.33
  19. Kensuke Kubota · 2 shared papers, 2017–2025 · strength 0.29
  20. Keiichi Yazawa · 2 shared papers, 2020–2022 · strength 0.25
  21. Kanechika Den · 1 shared paper, 2025 · strength 0.25
  22. Eriko Katsuta · 1 shared paper, 2025 · strength 0.22
  23. Ryutaro Mori · 1 shared paper, 2025 · strength 0.22
  24. Yasushi Ichikawa · 1 shared paper, 2025 · strength 0.22
  25. Noritoshi Kobayashi · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.